Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

NCT05317819 is registered in ClinicalTrials.gov with Polaris Group as lead sponsor.

NCT NCT05317819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05317819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Lead sponsor
Polaris Group
Phase
Phase 3
Overall status
Recruiting
Start date
March 14, 2022
Completion date
December 31, 2028
Enrollment
300 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, hepatocellular carcinoma